Comorbidity and survival disparities among black and white patients with breast cancer

JAMA

Volumn 294, Issue 14, 2005, Pages 1765-1772

  Tammemagi, C Martin ^a   Nerenz, David ^b   Neslund Dudas, Christine ^b   Feldkamp, Carolyn ^b   Nathanson, David ^b  

^a BROCK UNIVERSITY   (Canada)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUCASIAN; COMORBIDITY; FEMALE; HUMAN; MEDICAL RECORD; PRIORITY JOURNAL; RACE DIFFERENCE; REGRESSION ANALYSIS;

EID: 26444519200     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.14.1765     Document Type: Article

References (46)

1. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:342-355.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Dayal HH, Power RN, Chiu C. Race and socioeconomic status in survival from breast cancer. J Chronic Dis. 1982;35:675-683.
4. Bassett MT, Krieger N. Social class and blackwhite differences in breast cancer survival. Am J Public Health. 1986;76:1400-1403.
5. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer: results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272:947-954.
6. Weiss SE, Tartter PI, Ahmed S, et al. Ethnic differences in risk and prognostic factors for breast cancer. Cancer. 1995;76:268-274.
7. Krieger N, van den Eeden SK, Zava D, Okamoto A. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco Bay area. Ethn Dis. 1997;7:137-149.
8. Lyman GH, Kuderer NM, Lyman SL, Cox CE, Reintgen D, Baekey P. Importance of race on breast cancer survival. Ann Surg Oncol. 1997;4:80-87.
9. Simon MS, Severson RK. Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet Gynecol. 1997;176:S233-S239.
10. Velanovich V, Yood MU, Bawle U, et al. Racial differences in the presentation and surgical management of breast cancer. Surgery. 1999;125:375-379.
11. Yood MU, Johnson CC, Blount A, et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 1999;91:1487-1491.
12. Roetzheim RG, Gonzalez EC, Ferrante JM, Pal N, Van Durme DJ, Krischer JP. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer. 2000;89:2202-2213.
13. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer. 2000;88:114-123.
14. Newman LA, Carolin K, Simon M, et al. Impact of breast carcinoma on African-American women: the Detroit experience. Cancer. 2001;91:1834-1843.
15. Bradley CJ, Given CW, Roberts C. Race, socio-economic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490-496.
16. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment. Cancer. 2003;97:2853-2860.
17. Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004;101:1293-1301.
18. Satariano WA. Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol. 1992;47:24-31.
19. Satariano WA. Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol. 1993;330:1-11.
20. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-110.
21. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol. 1997;50:725-733.
22. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885-892.
23. Houterman S, Janssen-Heijnen ML, Verheij CD, et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer. 2004;90:2332-2337.
24. Nagel G, Wedding U, Rohrig B, Katenkamp D. The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol. 2004;130:664-670.
25. Elixhauser A, Steiner C, Palmer L. Clinical Classification Software (CCS), 2004. US Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/data/hcup/ccs.htm#download. Accessed February 28, 2005.
26. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Washington, DC: Public Health Service and Health Care Financing Administration; 1994. DHHS publication (PHS) 94-1260.
27. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103:792-802.
28. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, gender, raceethnicity and smoking predict adverse comorbidity, which in turn predicts lung cancer treatment and survival. J Clin Epidemiol. 2004;57:597-609.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
30. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56:221-229.
31. Beahrs OH; American Joint Committee on Cancer, American Cancer Society. Manual for Staging of Cancer, 4th ed. Philadelphia, Pa: Lippincott; 1992.
32. World Health Organization. The World Health Organization histological typing of lung tumours, 2nd ed. Am J Clin Pathol. 1982;77:123-136.
33. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87-90.
34. Kaplan D, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
35. Cox D. Regression models and life tables. J R Stat Soc A. 1972;34:187-220.
36. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340-349.
37. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. New York, NY: Oxford University Press; 1992.
38. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, England: Wiley; 1995.
39. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
40. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons; 1999.
41. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. New York, NY: Oxford University Press; 2003.
42. West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol. 1996;6:413-419.
43. Malenka DJ, McLerran D, Roos N, Fisher ES, Wennberg J. Using administrative data to describe casemix: a comparison with the medical record. J Clin Epidemiol. 1994;47:1027-1032.
44. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999;52:137-142.
45. Powell H, Lim LL, Heller RF. Accuracy of administrative data to assess comorbidity in patients with heart disease: an Australian perspective. J Clin Epidemiol. 2001;54:687-693.
46. Preen DB, Holman CD, Lawrence DM, Baynham NJ, Semmens JB. Hospital chart review provided more accurate comorbidity information than data from a general practitioner survey or an administrative database. J Clin Epidemiol. 2004;57:1295-1304.